Boehringer buys Swiss biotech in its lat­est M&A deal, go­ing the next-gen can­cer vac­cine route

Boehringer In­gel­heim has snapped up a Swiss biotech start­up and added their group as a new plat­form for the on­col­o­gy pipeline. 

The Ger­man bio­phar­ma com­pa­ny has bagged Gene­va-based AMAL Ther­a­peu­tics, pay­ing out an un­spec­i­fied up­front in a $358 mil­lion deal — cash, mile­stones and every­thing else, all in. Plus there’s 100 mil­lion eu­ros on the line for com­mer­cial mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER